Abivax Stock: 4.4% Decline at Close in Limited Trading Volumes
The biopharmaceutical company Abivax ended the session on October 22 at 76.10 euros, down 4.4% from the previous day's close of 79.60 euros. This decline occurred in a market that was also trending downward, with the CAC 40 losing 0.63% on the same day. Trading volumes were notably low, with only 0.07% of the capital changing hands during the session.
Weekly and Historical Performance
The biotechnology company, specializing in the development of treatments for inflammatory diseases, thus shows a weekly decline of 8.97%, bringing its valuation below the symbolic threshold of 80 euros. However, this weekly correction contrasts sharply with the stock's spectacular trajectory over longer time horizons. Over three months, Abivax's stock has surged by 744.6%, while its annual performance stands at 698.5%, nearly an eightfold increase in valuation. For comparison, the CAC 40 has gained 8.9% over the year. Abivax's market capitalization now stands at approximately 6 billion euros, positioning the company among the significant players in the Paris stock exchange's biotechnology sector. The current price of 76.10 euros remains 10.9% below the annual high of 85.40 euros recently reached, and is significantly above the annual low of 4.51 euros. This range illustrates the high volatility characterizing the stock, with a one-month volatility indicator at 10.75. The beta coefficient of -2.06 also indicates a strong inverse correlation with market movements.
Technical Analysis Overview
From a technical analysis standpoint, the Abivax stock is trading above its main moving averages, confirming the underlying bullish trend. The price is approximately 7% above the 50-session moving average, set at 71.11 euros, and more than 180% above the 200-session moving average, which stands at 26.46 euros. This configuration reflects a positive dynamic in the medium and long term, despite the recent correction. The 14-period Relative Strength Index stands at 67, a level that is in the high-neutral zone but has not yet reached the overbought zone typically set at 70. The MACD indicator shows a main line at 2.35, above the signal line at 2.08, with a positive histogram of 0.28, suggesting the persistence of bullish momentum. Bollinger Bands frame the price between a support at 66.76 euros and a resistance at 85.14 euros. The stock also trades between a support threshold identified at 68.60 euros and a technical resistance positioned at 83.60 euros. The stochastic oscillator generates a buy signal, while the Average True Range stands at 1.82, reflecting the average amplitude of daily price variations.
